Search IMDX
Insight Molecular Diagnostics Inc.
Nasdaq · CIK 1642380
Last close3.44
Daily change-0.03 (-0.86%)
10 Years gain-96.59%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
IMDX · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
54.9Momentum
0.0Acceleration
0.0Confidence
75.0Annual Revenue7
Quarterly Revenue30
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.9 / 25
Quality12.5 / 25
Capital Efficiency10.8 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 9.3053 percentage points.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 1974.8989 percentage points.
Heavy share dilution · HIGHDiluted share count increased 43.0295%.
Key Metrics
Revenue Growth TTM-72.7%OK
Revenue CAGR 3Y61.76%OK
Gross Margin61.87%OK
Operating Margin-3,499.05%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-15,847.7%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y43.03%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $4.06M | $2.30M | -$51.12M | -$22.18M | -$25.37M | 56.67% | -1,260.76% | -625.62% | n/a | 30.48M |
| 2025 FY Dec 31, 2024 | $1.88M | $740,000.00 | -$61.04M | -$20.69M | -$21.21M | 39.34% | -3,245.14% | -1,127.33% | n/a | 13.07M |
| 2024 FY Dec 31, 2023 | $1.50M | $413,000.00 | -$25.14M | -$23.33M | -$23.61M | 27.48% | -1,672.39% | -1,570.59% | -156.76% | 7.65M |
| 2023 FY Dec 31, 2022 | $958,000.00 | -$18,000.00 | -$18.00M | -$45.57M | -$49.91M | -1.88% | -1,878.6% | -5,209.6% | -61.06% | 5.54M |
| 2022 FY Dec 31, 2021 | $2.20M | $1.42M | -$53.73M | -$35.94M | -$38.19M | 64.6% | -2,444.27% | -1,737.4% | -144.83% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $1.05M | sum latest 4 fiscal quarters Revenue | OK | 0001642380-26-000011, 0001193125-25-274266 |
| Revenue Growth TTM | -72.7% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001642380-26-000011, 0001193125-25-274266 |
| Revenue CAGR 3Y | 61.76% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001642380-26-000004 |
| Revenue CAGR 5Y | 27.24% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001642380-26-000004 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001642380-26-000004 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001642380-26-000011, 0001193125-25-274266 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 61.87% | Gross Profit / Revenue | OK | 0001642380-26-000011, 0001193125-25-274266 |
| Operating Margin | -3,499.05% | Operating Income / Revenue | OK | 0001642380-26-000011, 0001193125-25-274266 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001642380-26-000011 |
| Current Ratio | 2x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.03 | Revenue / Diluted Shares | OK | 0001642380-26-000011, 0001193125-25-274266 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001642380-26-000004 |